electroCore Names Kelly Benning, Accomplished Healthcare Executive, as SVP of Truvaga
electroCore (NASDAQ: ECOR), a bioelectronic medicine and wellness company, has appointed Kelly Benning as Senior Vice President of Truvaga, effective July 21, 2025. Benning brings nearly 30 years of leadership experience in digital health, AI technologies, and consumer wellness.
Benning's impressive background includes pioneering the first FDA-cleared blood pressure monitoring watch and holding executive positions at LiveMetric, IBM Watson Health, CipherHealth, and other healthcare companies. In her new role, she will lead electroCore's consumer wellness division, focusing on strategic partnerships and expanding access to consumer devices through the company's digital wellness platform, Truvaga.
[ "Appointment of experienced executive with nearly 30 years in digital health and AI technologies", "Strategic focus on expanding direct-to-consumer market access", "Addition of leader with proven track record in FDA-cleared medical device commercialization" ]electroCore (NASDAQ: ECOR), azienda di medicina bioelettronica e benessere, ha nominato Kelly Benning vicepresidente senior di Truvaga, a decorrere dal 21 luglio 2025. Benning porta con sé quasi 30 anni di esperienza dirigenziale nel digitale sanitario, nelle tecnologie di intelligenza artificiale e nel settore del benessere dei consumatori.
Nel suo percorso professionale ha guidato lo sviluppo del primo orologio per il monitoraggio della pressione arteriosa approvato dalla FDA e ha ricoperto ruoli dirigenziali presso LiveMetric, IBM Watson Health, CipherHealth e altre aziende sanitarie. Nel suo nuovo ruolo coordinerà la divisione consumer wellness di electroCore, concentrandosi su partnership strategiche e sull'ampliamento dell'accesso ai dispositivi consumer tramite la piattaforma digitale Truvaga.
Punti chiave: nomina di una dirigente con quasi 30 anni di esperienza in digital health e AI; focus strategico sull'espansione dell'accesso diretto al consumatore; inserimento di una leader con comprovata esperienza nella commercializzazione di dispositivi medici approvati dalla FDA.
electroCore (NASDAQ: ECOR), empresa de medicina bioelectrónica y bienestar, ha nombrado a Kelly Benning vicepresidenta sénior de Truvaga, con efecto desde el 21 de julio de 2025. Benning aporta casi 30 años de experiencia en liderazgo en salud digital, tecnologías de IA y bienestar del consumidor.
En su trayectoria lideró el desarrollo del primer reloj de monitorización de la presión arterial autorizado por la FDA y ha ocupado cargos ejecutivos en LiveMetric, IBM Watson Health, CipherHealth y otras compañías sanitarias. En su nuevo puesto dirigirá la división de bienestar para consumidores de electroCore, centrándose en alianzas estratégicas y en ampliar el acceso a dispositivos de consumo a través de la plataforma digital Truvaga.
Puntos clave: incorporación de una ejecutiva con casi 30 años en salud digital e IA; enfoque estratégico en la expansión del acceso directo al consumidor; suma de una líder con historial probado en la comercialización de dispositivos médicos aprobados por la FDA.
electroCore (NASDAQ: ECOR)는 생체 전자 의학 및 웰니스 기업으로, Kelly Benning을 Truvaga 수석 부사장으로 2025년 7월 21일부로 임명했습니다. Benning은 디지털 헬스, 인공지능 기술 및 소비자 웰니스 분야에서 거의 30년의 리더십 경험을 보유하고 있습니다.
그녀는 FDA 승인 혈압 측정 시계의 초기 개발을 주도했으며 LiveMetric, IBM Watson Health, CipherHealth 등 여러 헬스케어 기업에서 임원직을 역임했습니다. 이번 역할에서 그녀는 electroCore의 소비자 웰니스 부문을 이끌며 전략적 파트너십을 추진하고 디지털 웰니스 플랫폼 Truvaga를 통해 소비자 기기 접근성을 확대하는 데 주력할 예정입니다.
핵심 포인트: 디지털 헬스 및 AI 분야에서 거의 30년 경력의 경험 많은 임원 임명; 직접 소비자 시장 접근성 확대에 주력; FDA 승인 의료기기 상용화에 입증된 성과를 가진 리더 영입.
electroCore (NASDAQ: ECOR), entreprise de médecine bioélectronique et de bien-être, a nommé Kelly Benning au poste de Senior Vice President de Truvaga, à compter du 21 juillet 2025. Benning apporte près de 30 ans d'expérience managériale dans la santé numérique, les technologies d'IA et le bien-être des consommateurs.
Parmi ses réalisations, elle a contribué au développement de la première montre de surveillance de la tension artérielle approuvée par la FDA et a occupé des postes de direction chez LiveMetric, IBM Watson Health, CipherHealth et d'autres sociétés de santé. Dans ses nouvelles fonctions, elle dirigera la division bien-être grand public d'electroCore, en se concentrant sur des partenariats stratégiques et l'élargissement de l'accès aux appareils grand public via la plateforme digitale Truvaga.
Points clés : nomination d'une dirigeante expérimentée avec près de 30 ans dans la santé numérique et l'IA ; focalisation stratégique sur l'expansion de l'accès direct au consommateur ; renfort d'une leader ayant fait ses preuves dans la commercialisation d'appareils médicaux approuvés par la FDA.
electroCore (NASDAQ: ECOR), ein Unternehmen für bioelektronische Medizin und Wellness, hat Kelly Benning als Senior Vice President von Truvaga mit Wirkung zum 21. Juli 2025 ernannt. Benning bringt fast 30 Jahre Führungserfahrung in Digital Health, KI-Technologien und Consumer-Wellness mit.
Zu ihrer Laufbahn gehört die Mitentwicklung der ersten von der FDA zugelassenen Blutdruckmessuhr sowie Führungspositionen bei LiveMetric, IBM Watson Health, CipherHealth und weiteren Healthcare-Unternehmen. In ihrer neuen Rolle wird sie die Consumer-Wellness-Sparte von electroCore leiten, mit Fokus auf strategische Partnerschaften und die Ausweitung des Zugangs zu Verbrauchergeräten über die digitale Wellness-Plattform Truvaga.
Kernpunkte: Ernennung einer erfahrenen Führungskraft mit fast 30 Jahren in Digital Health und KI; strategischer Fokus auf die Erweiterung des Direkt-konsumenten-Marktzugangs; Hinzunahme einer Führungspersönlichkeit mit nachweislicher Erfolgsbilanz bei der Kommerzialisierung von FDA-zugelassenen Medizinprodukten.
- None.
- None.
ROCKAWAY, N.J., Aug. 12, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Kelly Benning has been hired as the Senior Vice President of Truvaga, effective July 21, 2025.
Ms. Benning, who brings almost three decades of leadership experience across digital health, AI-enabled technologies, and consumer wellness, will lead electroCore’s consumer wellness division.
Kelly Benning, electroCore's Senior Vice President of Truvaga
“As an ever-increasing number of people are beginning to be more aware of the link between their lifestyle choices and well-being, wellness has evolved from a niche trend to a fundamental part of the daily lives of many, shifting the focus of the wellness market to a more personalized, consumer-centric dynamic,” said Ms. Benning. “It’s important that we meet the demand for consumer-led, lifestyle-based solutions by continuing to innovate and refine our technology, and empowering people to confidently take control of their own well-being. My focus will be on emphasizing electroCore’s commitment to research-based, trustworthy health solutions. I plan to use strategic partnerships to provide more accessibility to those looking to purchase our consumer devices. We’re not just growing a brand; we’re building a movement centered around approachable, personal, and science-backed wellness solutions.”
Ms. Benning has successfully brought pioneering digital health products to market, including the first and only FDA-cleared watch to monitor blood pressure, delivering breakthrough solutions and expertly navigating the commercialization process. Her interest in AI and machine-learning has led her to drive continual innovation and consistent market adoption of technology at the intersection of healthcare, data, and consumer experience.
Throughout her career, Ms. Benning has worked with a multitude of consumer retailers, payors, providers, and healthcare enterprises to bring clinically impactful and commercially successful products to market. She currently serves as Senior Vice President of Truvaga, electroCore’s digital wellness platform, where she leads strategy, operations, and growth. Prior to joining electroCore, Ms. Benning held executive leadership roles including President at LiveMetric, Vice President of Sales at IBM Watson Health, and senior roles at CipherHealth, Savonix, Healthgrades, and National Jewish Health. Ms. Benning holds a Bachelor of Arts in Kinesiology and Exercise Science from the University of Colorado Boulder.
“Bringing a proven and accomplished executive like Kelly to electroCore is the first of several benefits from our accelerating investment to support electroCore’s growth,” commented Dan Goldberger, CEO of electroCore. “I am confident that Kelly has the right skills to expand our direct-to-consumer strategy.”
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the Company commercializes its Truvaga™ products, handheld, and personal use nVNS products utilizing bioelectronic technologies, to promote general wellness and human performance.
For more information, visit www.electrocore.com.
Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about the anticipated contributions of a newly appointed executive, the Company’s future business strategies, growth opportunities, prospects, product development, and market expansion, and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” and other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to use strategic partnerships to provide more accessibility to those looking to purchase our consumer devices, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize its products, electroCore’s results of operations and financial performance, inflation and currency fluctuations, and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall economic and market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.
Contact
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bd0a2b17-cb17-4c9c-bbed-22f1bca42304
FAQ
Who is Kelly Benning and what is her new role at electroCore (NASDAQ: ECOR)?
What is Kelly Benning's professional background before joining electroCore?
What will be Kelly Benning's main responsibilities at electroCore?
What is Truvaga at electroCore?
